Antiretroviral therapy for prevention is a combination strategy.
In the past several years, the debate of "treatment vs prevention" has shifted with the introduction of the concept of "treatment as prevention," (TasP), stemming from a series of compelling observational, ecological, and modeling studies as well as HPTN 052, a randomized clinical trial, demonstrating that use of ART is associated with a decrease in HIV transmission. In addition to TasP being viewed as 1 intervention in a combination strategy for HIV Prevention, TasP is, in and of itself, a combination of multiple interventions that need to be implemented with high coverage in order to achieve its potential impact.
ICAP-Columbia University, Mailman School of Public Health, New York, NY 10032, USA. MM3780@columbia.edu
Margaret L
ML
McNairy
Myron
M
Cohen
Wafaa M
WM
El-Sadr
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002944:Circumcision, Male / Q000706:statistics & numerical data*; D003131:Combined Modality Therapy; D003376:Counseling; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D006297:Health Services Accessibility; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D040242:Risk Reduction Behavior; D014481:United States / Q000453:epidemiology; D016903:Drug Monitoring
D019380:Anti-HIV Agents